Novartis Cosentyx Gains FDA Approval for Pediatric HS
BASEL, Switzerland, March 13, 2026 Global pharmaceutical leader Novartis has announced that the U.S. Food and Drug Administration (FDA)...
Novartis
Advertisement
Novartis Closes $12B Avidity Acquisition
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
Novartis Launches Flagship U.S. Hub to Secure Drug Manufacturing
EAST HANOVER, N.J. — December 12, 2025 — Novartis, a global innovative medicines company, has officially broken ground on...
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Novartis Fabhalta® Slows Kidney Function Decline in Phase III IgAN Study
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
Advertisements
Novartis wins FDA approval for first oral BTKi in chronic urticaria
EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has...
Novartis to Present Key Prostate and Breast Cancer Data at ESMO
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
Monte Rosa and Novartis Expand Degrader Alliance in Immunology
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
Pulse Biosciences Secures FDA IDE Approval to Launch Clinical Trial of nsPFA Cardiac Surgery System for Atrial Fibrillation
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
Novartis to Acquire Tourmaline Bio, Expanding ASCVD Pipeline
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
Advertisement
